{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:24:29Z","timestamp":1769549069660,"version":"3.49.0"},"reference-count":201,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"King Abdullah University of Science and Technology (KAUST)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Psychedelics such as lysergic acid diethylamide (LSD), psilocybin (magic mushrooms), and mescaline exhibit intense effects on the human brain and behaviour. In recent years, there has been a surge in studies investigating these drugs because clinical studies have shown that these once banned drugs are well tolerated and efficacious in medically supervised low doses called microdosing. Psychedelics have demonstrated efficacy in treating neuropsychiatric maladies such as difficult to treat anxiety, depression, mood disorders, obsessive compulsive disorders, suicidal ideation, posttraumatic stress disorder, and also in treating substance use disorders. The primary mode of action of psychedelics is activation of serotonin 5-HT2A receptors affecting cognition and brain connectivity through the modulation of several downstream signalling pathways via complex molecular mechanisms. Some atypical antipsychotic drugs (APDs) primarily exhibit pharmacological actions through 5-HT2A receptors, which are also the target of psychedelic drugs. Psychedelic drugs including the newer second generation along with the glutamatergic APDs are thought to mediate pharmacological actions through a common pathway, i.e., a complex serotonin\u2013glutamate receptor interaction in cortical neurons of pyramidal origin. Furthermore, psychedelic drugs have been reported to act via a complex interplay between 5HT2A, mGlu2\/3, and NMDA receptors to mediate neurobehavioral and pharmacological actions. Findings from recent studies have suggested that serotoninergic and glutamatergic neurotransmissions are very closely connected in producing pharmacological responses to psychedelics and antipsychotic medication. Emerging hypotheses suggest that psychedelics work through brain resetting mechanisms. Hence, there is a need to dig deeply into psychedelic neurobiology to uncover how psychedelics could best be used as scientific tools to benefit psychiatric disorders including schizophrenia.<\/jats:p>","DOI":"10.3390\/ph15050640","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T03:16:55Z","timestamp":1653362215000},"page":"640","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["New Paradigms of Old Psychedelics in Schizophrenia"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0202-8691","authenticated-orcid":false,"given":"Danish","family":"Mahmood","sequence":"first","affiliation":[{"name":"Department of Pharmacology & Toxicology, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sattam K.","family":"Alenezi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Toxicology, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md. Jamir","family":"Anwar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Toxicology, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2927-8167","authenticated-orcid":false,"given":"Faizul","family":"Azam","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry & Pharmacognosy, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-797X","authenticated-orcid":false,"given":"Kamal A.","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, Unaizah College of Pharmacy, Qassim University, Unaizah 51911, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariusz","family":"Jaremko","sequence":"additional","affiliation":[{"name":"Smart-Health Initiative (SHI) and Red Sea Research Center (RSRC), Division of Biological and Environmental Sciences and Engineering (BESE), King Abdullah University of Science and Technology (KAUST), Thuwal 23955, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Saha, S., Chant, D., Welham, J., and McGrath, J. (2005). A Systematic Review of the Prevalence of Schizophrenia. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020141"},{"key":"ref_2","unstructured":"WHO (2021, November 07). Schizophrenia. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/schizophrenia."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: A Concise Overview of Incidence, Prevalence, and Mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature06612","article-title":"Identification of a serotonin\/glutamate receptor complex implicated in psychosis","volume":"452","author":"Ang","year":"2008","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1176\/appi.focus.20160006","article-title":"Schizophrenia: An Overview","volume":"14","author":"Rahman","year":"2016","journal-title":"Focus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/schbul\/sbj019","article-title":"Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?","volume":"32","author":"Bola","year":"2006","journal-title":"Schizophr. Bull."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","article-title":"Half a century of antipsychotics and still a central role for dopamine D2 receptors","volume":"27","author":"Kapur","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/070674370204700106","article-title":"Atypical Antipsychotics: Mechanism of Action","volume":"47","author":"Seeman","year":"2002","journal-title":"Can. J. Psychiatry"},{"key":"ref_10","first-page":"495","article-title":"Fifty years chlorpromazine: A historical perspective","volume":"3","author":"Ban","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0010-440X(99)90082-2","article-title":"A history of antipsychotic drug development","volume":"40","author":"Shen","year":"1999","journal-title":"Compr. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1527-3458.2004.tb00030.x","article-title":"Aripiprazole: A novel atypical antipsychotic drug with a uniquely robust pharmacology","volume":"10","author":"Davies","year":"2004","journal-title":"CNS Drug Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1568007024606221","article-title":"Current status of antipsychotic treatment","volume":"1","author":"Conley","year":"2002","journal-title":"Curr. Drug Targets CNS Neurol. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/070674370404900504","article-title":"New antipsychotics, compliance, quality of life, and subjective tolerability\u2014Are patients better off?","volume":"49","author":"Awad","year":"2004","journal-title":"Can. J. Psychiatr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11920-005-0085-5","article-title":"First- and second-generation antipsychotic medication and cognitive processing in schizophrenia","volume":"7","author":"Weickert","year":"2005","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.14074su1c.02","article-title":"Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia","volume":"77","author":"Green","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","article-title":"Secondary negative symptomsA review of mechanisms, assessment and treatment","volume":"186","author":"Kirschner","year":"2017","journal-title":"Schizophr. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ahj.2005.02.007","article-title":"Schizophrenia and increased risks of cardiovascular disease","volume":"150","author":"Hennekens","year":"2005","journal-title":"Am. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/pds.1325","article-title":"Mortality in schizophrenia","volume":"15","author":"Auquier","year":"2006","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.4249\/scholarpedia.3634","article-title":"Dopamine and schizophrenia","volume":"10","author":"Seeman","year":"2007","journal-title":"Scholarpedia"},{"key":"ref_21","first-page":"A42","article-title":"Congruencies in Increased Mortality Rates, Years of Potential Life Lost, and Causes of Death Among Public Mental Health Clients in Eight States","volume":"3","author":"Colton","year":"2006","journal-title":"Prev. Chronic Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/jama.298.15.1794","article-title":"Severe mental illness and risk of cardiovascular disease","volume":"298","author":"Newcomer","year":"2007","journal-title":"JAMA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4103\/0253-7176.119471","article-title":"Metabolic syndrome in schizophrenia","volume":"35","author":"Malhotra","year":"2013","journal-title":"Indian J. Psychol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0019-5545.148532","article-title":"Sexual dysfunctions in schizophrenia: Professionals and patients perspectives","volume":"57","author":"Tharoor","year":"2015","journal-title":"Indian J. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am. J. Psychiatry"},{"key":"ref_26","first-page":"141","article-title":"Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis","volume":"1","author":"Tamminga","year":"2002","journal-title":"Curr. Drug Targets"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_28","first-page":"44","article-title":"Optimizing treatment with clozapine","volume":"59","author":"Conley","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","article-title":"Evidence of clozapine\u2019s effectiveness in schizophrenia: A systematic review and meta-analysis of randomized trials","volume":"156","author":"Wahlbeck","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"ref_30","first-page":"37","article-title":"Antipsychotics\u2014The Future of Schizophrenia Treatment","volume":"16","author":"Beaumont","year":"2000","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: A critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on Quality of Life of second- vs. first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1176\/appi.ajp.160.8.1396","article-title":"Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol","volume":"160","author":"Lieberman","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/sj.npp.1300157","article-title":"Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: A 52-week randomized trial of clozapine vs. chlorpromazine","volume":"28","author":"Lieberman","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e04","DOI":"10.4088\/JCP.0207e04","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Efficacy, safety and cost outcomes of CATIE and other trials","volume":"68","author":"Lieberman","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1176\/appi.ajp.162.5.947","article-title":"Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial","volume":"162","author":"Schooler","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry"},{"key":"ref_40","unstructured":"British Association for Psychopharmacology of Schizophrenia (2021, November 07). Evidence-Based Guidelines for the Pharmacological Treatment of Schizophrenia: Recommendations from the British Association for Psychopharmacology. Available online: https:\/\/www.bap.org.uk."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis","year":"2006","journal-title":"Schizophr. Bull."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1017\/S0033291716002014","article-title":"Two distinct patterns of treatment resistance: Clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses","volume":"46","author":"Lally","year":"2016","journal-title":"Psychol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/wps.20522","article-title":"Antipsychotic drugs: Challenges and future directions","volume":"17","author":"Howes","year":"2018","journal-title":"World Psychiatry"},{"key":"ref_46","first-page":"175","article-title":"The Pharmacologic Treatment of Schizophrenia\u20142021","volume":"325","author":"Goff","year":"2021","journal-title":"JAMA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.119.260281","article-title":"SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D(2) Receptor Mechanism of Action","volume":"371","author":"Dedic","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A Non\u2013D2-Receptor-Binding Drug for the Treatment of Schizophrenia","volume":"382","author":"Koblan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.13249","article-title":"Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies","volume":"143","author":"Andersen","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2147\/RMHP.S300656","article-title":"The use of classic hallucinogens\/psychedelics in a therapeutic context: Healthcare policy opportunities and challenges","volume":"14","author":"Bouso","year":"2021","journal-title":"Risk Manag. Healthc. Policy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.tins.2008.12.005","article-title":"Psychedelics and schizophrenia","volume":"32","author":"Sealfon","year":"2009","journal-title":"Trends Neurosci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00213-017-4822-3","article-title":"Psychedelics and related drugs: Therapeutic possibilities, mechanisms and regulation","volume":"235","author":"Curran","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/a-1721-2914","article-title":"Classic Psychedelic Drugs: Update on Biological Mechanisms","volume":"55","author":"Vollenweider","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"ref_54","unstructured":"Goodman, A.G., Rall, T.W., and Nies, A.S.T.P. (1990). Drug addiction and drug abuse. Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics, McGraw Hill."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.tips.2017.08.003","article-title":"Psychedelic Drugs in Biomedicine","volume":"38","author":"Kyzar","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/02791072.2020.1718250","article-title":"Psychedelic Microdosing: Prevalence and Subjective Effects","volume":"52","author":"Cameron","year":"2020","journal-title":"J. Psychoact. Drugs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1021\/acschemneuro.8b00692","article-title":"Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents","volume":"10","author":"Cameron","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e66920","DOI":"10.7554\/eLife.66920","article-title":"Asking questions of psychedelic microdosing","volume":"10","author":"Cameron","year":"2021","journal-title":"eLife"},{"key":"ref_60","first-page":"383","article-title":"Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges","volume":"85","author":"Jungaberle","year":"2017","journal-title":"Fortschr. Neurol. Psychiatr."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1089\/jpm.2017.0684","article-title":"Taking Psychedelics Seriously","volume":"21","author":"Byock","year":"2018","journal-title":"J. Palliat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as Medicines: An Emerging New Paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/0269881114565653","article-title":"Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population","volume":"29","author":"Hendricks","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression","volume":"11","author":"Hibicke","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"ref_65","first-page":"461","article-title":"Preliminary Report on the Effects of a Low Dose of LSD on Resting-State Amygdala Functional Connectivity","volume":"5","author":"Bershad","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Raval, N.R., Johansen, A., Donovan, L.L., Ros, N.F., Ozenne, B., Hansen, H.D., and Knudsen, G.M. (2021). A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT(2A) Receptor Density in the Pig Brain. Int. J. Mol. Sci., 22.","DOI":"10.20944\/preprints202011.0742.v1"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"Giribaldi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"727117","DOI":"10.3389\/fpsyt.2021.727117","article-title":"Psychedelics and Other Psychoplastogens for Treating Mental Illness","volume":"12","author":"Vargas","year":"2021","journal-title":"Front. Psychiatry"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3389\/fphar.2018.00733","article-title":"Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development","volume":"9","author":"Schenberg","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and Psychedelic-Assisted Psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1556\/2054.2019.018","article-title":"Making psychedelics into medicines: The politics and paradoxes of medicalization","volume":"4","author":"Noorani","year":"2020","journal-title":"J. Psychedelic Stud."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S2215-0366(15)00576-3","article-title":"Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA","volume":"3","author":"Mithoefer","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study","volume":"3","author":"Bolstridge","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Strumila, R., Nobile, B., Korsakova, L., Lengvenyte, A., Olie, E., Lopez-Castroman, J., Guillaume, S., and Courtet, P. (2021). Psilocybin, a naturally occurring indoleamine compound, could be useful to prevent suicidal behaviors. Pharmaceuticals, 14.","DOI":"10.3390\/ph14121213"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Slocum, S.T., DiBerto, J.F., and Roth, B.L. (2021). Molecular insights into psychedelic drug action. J. Neurochem.","DOI":"10.1111\/jnc.15540"},{"key":"ref_79","unstructured":"Hwang, K.A.J., and Saadabadi, A. (2022). Lysergic Acid Diethylamide (LSD), StatPearls Publishing."},{"key":"ref_80","unstructured":"Lee, M.A., and Shlain, B. (1992). Acid Dreams: The Complete Social History of LSD: The CIA, the Sixties, and Beyond, Grove Weidenfeld."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/AIA.0b013e31811f4613","article-title":"From LSD to the IRB: Henry Beecher\u2019s psychedelic research and the foundation of clinical ethics","volume":"45","author":"Mashour","year":"2007","journal-title":"Int. Anesthesiol. Clin."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/embr.201338282","article-title":"Mind-altering drugs and research: From presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on \u201cDrugs and Science\u201d","volume":"15","author":"Nutt","year":"2014","journal-title":"EMBO Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1177\/070674370505000703","article-title":"Flashback: Psychiatric experimentation with LSD in historical perspective","volume":"50","author":"Dyck","year":"2005","journal-title":"Can. J. Psychiatry"},{"key":"ref_84","unstructured":"Kvam, T.-M., Stewart, L.H., and Andreassen, O.A. (2018). Psychedelic drugs in the treatment of anxiety, depression and addiction. Tidsskr. Den Nor. Laegeforening, 138."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3389\/fpsyt.2019.00943","article-title":"Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials","volume":"10","author":"Fuentes","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"711255","DOI":"10.3389\/fphar.2021.711255","article-title":"Role of the 5-HT(2A) Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin","volume":"12","author":"Holze","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0269881114555249","article-title":"LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects","volume":"29","author":"Gasser","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00213-019-05417-7","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers","volume":"237","author":"Family","year":"2020","journal-title":"Psychopharmacology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00213-014-3714-z","article-title":"LSD enhances suggestibility in healthy volunteers","volume":"232","author":"Kaelen","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1007\/s00213-015-4014-y","article-title":"LSD enhances the emotional response to music","volume":"232","author":"Kaelen","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_93","unstructured":"Hwang, K.A.J., and Saadabadi, A. (2018). Lysergic Acid Diethylamide (LSD), StatPearls Publishing."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"814","DOI":"10.3389\/fphar.2017.00814","article-title":"LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation","volume":"8","author":"Kraehenmann","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e35082","DOI":"10.7554\/eLife.35082","article-title":"Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor","volume":"7","author":"Preller","year":"2018","journal-title":"eLife"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1037\/0033-2909.129.4.495","article-title":"Hypnosis and clinical pain","volume":"129","author":"Patterson","year":"2003","journal-title":"Psychol. Bull."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/00029157.2012.738613","article-title":"Suggestion in the treatment of depression","volume":"55","author":"Kirsch","year":"2013","journal-title":"Am. J. Clin. Hypn."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopsych.2015.08.003","article-title":"Lysergic Acid Diethylamide and Psilocybin Revisited","volume":"78","author":"Geyer","year":"2015","journal-title":"Biol. Psychiatry"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/1874402801104010020","article-title":"A historical review of MDMA","volume":"4","author":"Karch","year":"2011","journal-title":"Open Forensic Sci. J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1037\/pha0000084","article-title":"Clinical applications of hallucinogens: A review","volume":"24","author":"Kersgaard","year":"2016","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1590\/1516-4446-2020-0980","article-title":"3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: An open label pilot study in Brazil","volume":"43","author":"Jardim","year":"2020","journal-title":"Braz. J. Psychiatry"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1755-5949.2008.00059.x","article-title":"The pharmacology of lysergic acid diethylamide: A review","volume":"14","author":"Passie","year":"2008","journal-title":"CNS Neurosci. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addict. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","article-title":"Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor","volume":"60","author":"Bunzow","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1126\/science.1166127","article-title":"The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator","volume":"323","author":"Fontanilla","year":"2009","journal-title":"Science"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/2061052a0","article-title":"Tryptamine, N,N-Dimethyltryptamine, N,N-Dimethyl-5-hydroxytryptamine and 5-Methoxytryptamine in Human Blood and Urine","volume":"206","author":"Franzen","year":"1965","journal-title":"Nature"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/dta.422","article-title":"A critical review of reports of endogenous psychedelic N, N-dimethyltryptamines in humans: 1955\u20132010","volume":"4","author":"Barker","year":"2012","journal-title":"Drug Test. Anal."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0006-2952(80)90169-0","article-title":"Metabolism of the hallucinogen N,N-dimethyltryptamine in rat brain homogenates","volume":"29","author":"Barker","year":"1980","journal-title":"Biochem. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/bmc.2981","article-title":"LC\/MS\/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate","volume":"27","author":"Barker","year":"2013","journal-title":"Biomed. Chromatogr. BMC"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0006-2944(77)90088-6","article-title":"The in vitro identification of dimethyltryptamine (DMT) in mammalian brain and its characterization as a possible endogenous neuroregulatory agent","volume":"18","author":"Christian","year":"1977","journal-title":"Biochem. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/geno.1999.5960","article-title":"Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization","volume":"61","author":"Thompson","year":"1999","journal-title":"Genomics"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.mehy.2008.07.052","article-title":"Endogenous hallucinogens as ligands of the trace amine receptors: A possible role in sensory perception","volume":"72","author":"Wallach","year":"2009","journal-title":"Med. Hypotheses"},{"key":"ref_114","first-page":"104","article-title":"DPT as an adjunct in psychotherapy of alcoholics","volume":"8","author":"Grof","year":"1973","journal-title":"Int. Pharm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/02791072.1977.10472060","article-title":"Psychedelic Drug (DPT)-Assisted Psychotherapy with Alcoholics: A Controlled Study","volume":"9","author":"Rhead","year":"1977","journal-title":"J. Psychedelic Drugs"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/archpsyc.1973.01750360047006","article-title":"Low doses of dipropyltryptamine in psychotherapy","volume":"28","author":"Soskin","year":"1973","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF01532413","article-title":"Mystical and archetypal experiences of terminal patients in DPT-assisted psychotherapy","volume":"17","author":"Richards","year":"1978","journal-title":"J. Relig. Health"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02791072.1977.10472020","article-title":"The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients","volume":"9","author":"Richards","year":"1977","journal-title":"J. Psychedelic Drugs"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2190\/NGUB-V4RM-T7DC-XTH3","article-title":"DPT as an Adjunct in Brief Psychotherapy with Cancer Patients","volume":"10","author":"Richards","year":"1980","journal-title":"OMEGA\u2014J. Death Dying"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.imlet.2020.10.001","article-title":"Psychedelics as a novel approach to treating autoimmune conditions","volume":"228","author":"Thompson","year":"2020","journal-title":"Immunol. Lett."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1177\/0269881107077734","article-title":"Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis","volume":"21","author":"Heekeren","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"ref_122","first-page":"157","article-title":"Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction","volume":"7","author":"Griffiths","year":"2014","journal-title":"Curr. Drug Abus. Rev."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Barker, S.A. (2022). Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT. Psychopharmacology, 1\u201315.","DOI":"10.1007\/s00213-022-06065-0"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cber.18960290145","article-title":"Ueber cacteenalkaloide","volume":"29","author":"Heffter","year":"1896","journal-title":"Ber. Dtsch. Chem. Ges."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/00005053-195707000-00012","article-title":"Pharmacodynamics of LSD and mescaline","volume":"125","author":"Rinkel","year":"1957","journal-title":"J. Nerv. Ment. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0010-440X(62)80024-8","article-title":"Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures","volume":"3","author":"Hollister","year":"1962","journal-title":"Compr. Psychiatry"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/15313204.2013.843138","article-title":"Indigenous Supports for Recovery from Alcoholism and Drug Abuse: The Native American Church","volume":"22","author":"Prue","year":"2013","journal-title":"J. Ethn. Cult. Divers. Soc. Work"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.biopsych.2005.06.038","article-title":"Psychological and cognitive effects of long-term peyote use among Native Americans","volume":"58","author":"Halpern","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.coph.2004.08.008","article-title":"PCP: From pharmacology to modelling schizophrenia","volume":"5","author":"Morris","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coph.2006.08.013","article-title":"NMDA receptors and schizophrenia","volume":"7","author":"Kristiansen","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3389\/fpsyt.2020.00432","article-title":"Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality","volume":"11","author":"Navarrete","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neubiorev.2010.05.002","article-title":"Individual differences in prefrontal cortex function and the transition from drug use to drug dependence","volume":"35","author":"George","year":"2010","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.biopsych.2011.05.025","article-title":"The neural basis of drug stimulus processing and craving: An activation likelihood estimation meta-analysis","volume":"70","author":"Chase","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1073\/pnas.1212185110","article-title":"Dorsolateral prefrontal and orbitofrontal cortex interactions during self-control of cigarette craving","volume":"110","author":"Hayashi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/j.1460-9568.2010.07590.x","article-title":"Common biology of craving across legal and illegal drugs\u2014A quantitative meta-analysis of cue-reactivity brain response","volume":"33","author":"Gallinat","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s42234-020-0040-0","article-title":"Biomarkers and neuromodulation techniques in substance use disorders","volume":"6","author":"Habelt","year":"2020","journal-title":"Bioelectron. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1369-1600.2011.00352.x","article-title":"Validating incentive salience with functional magnetic resonance imaging: Association between mesolimbic cue reactivity and attentional bias in alcohol-dependent patients","volume":"17","author":"Loeber","year":"2012","journal-title":"Addict. Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/alcalc\/agn100","article-title":"Biochemical and Neurotransmitter Changes Implicated in Alcohol-Induced Brain Damage in Chronic or \u2018Binge Drinking\u2019 Alcohol Abuse","volume":"44","author":"Ward","year":"2009","journal-title":"Alcohol Alcohol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3233\/BPL-150022","article-title":"Serotonergic Neuroplasticity in Alcohol Addiction","volume":"1","author":"Belmer","year":"2016","journal-title":"Brain Plast."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1569-7339(10)70099-0","article-title":"The role of serotonin in drug addiction","volume":"Volume 21","author":"Pum","year":"2010","journal-title":"Handbook of Behavioral Neuroscience"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.pnpbp.2004.01.009","article-title":"Lymphocytes as a neural probe: Potential for studying psychiatric disorders","volume":"28","author":"Gladkevich","year":"2004","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"ref_142","first-page":"273","article-title":"Connecting cytokines and brain: A review of current issues","volume":"17","author":"Quan","year":"2002","journal-title":"Histol. Histopathol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"17453","DOI":"10.1038\/s41598-019-53745-7","article-title":"Immunophenotypes associated with bipolar disorder and lithium treatment","volume":"9","author":"Wu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrg2484","article-title":"RNA-Seq: A revolutionary tool for transcriptomics","volume":"10","author":"Wang","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.euroneuro.2015.10.009","article-title":"Transcriptomics and the mechanisms of antidepressant efficacy","volume":"26","author":"Hodgson","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jpsychires.2019.03.028","article-title":"Peripheral blood microRNA levels in females with cocaine use disorder","volume":"114","author":"Viola","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2001-1326-3-7","article-title":"Clinical proteomic biomarkers: Relevant issues on study design & technical considerations in biomarker development","volume":"3","author":"Frantzi","year":"2014","journal-title":"Clin. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"14003","DOI":"10.1038\/npjschz.2014.3","article-title":"The proteome of schizophrenia","volume":"1","author":"Nascimento","year":"2015","journal-title":"NPJ Schizophr."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41398-018-0219-2","article-title":"Proteomics for blood biomarker exploration of severe mental illness: Pitfalls of the past and potential for the future","volume":"8","author":"Comes","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e13553","DOI":"10.1097\/MD.0000000000013553","article-title":"Mass spectrometry identification of potential biomarker proteins in the 150-kD electrophoretic band in patients with schizophrenia","volume":"97","author":"Xu","year":"2018","journal-title":"Medicine"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3389\/fpsyt.2019.00885","article-title":"Proteomics in Schizophrenia: A Gateway to Discover Potential Biomarkers of Psychoneuroimmune Pathways","volume":"10","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"8627","DOI":"10.1073\/pnas.1801609115","article-title":"Acetyl-l-carnitine deficiency in patients with major depressive disorder","volume":"115","author":"Nasca","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41398-019-0518-2","article-title":"Plasma neurofilament light chain concentration is increased in anorexia nervosa","volume":"9","author":"Nilsson","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s00415-019-09567-8","article-title":"Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders","volume":"267","author":"Katisko","year":"2020","journal-title":"J. Neurol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-3-030-05542-4_14","article-title":"Metabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia","volume":"1118","author":"Quintero","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-3-030-21735-8_10","article-title":"Metabolomics Biomarkers for Precision Psychiatry","volume":"1161","author":"Shih","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Gim\u00e9nez, J.L. (2015). Epigenetic Biomarkers and Diagnostics, Academic Press.","DOI":"10.1016\/B978-0-12-801899-6.00001-2"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/10408363.2017.1410520","article-title":"Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory","volume":"54","author":"Tollefsbol","year":"2017","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41380-019-0601-3","article-title":"Epigenetic mechanisms in schizophrenia and other psychotic disorders: A systematic review of empirical human findings","volume":"25","author":"Smigielski","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/jhg.2013.65","article-title":"DNA methylation of the BDNF gene and its relevance to psychiatric disorders","volume":"58","author":"Ikegame","year":"2013","journal-title":"J. Hum. Genet."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.mp.4001637","article-title":"BDNF in schizophrenia, depression and corresponding animal models","volume":"10","author":"Angelucci","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psyneuen.2018.12.226","article-title":"Allele-specific DNA methylation level of FKBP5 is associated with post-traumatic stress disorder","volume":"103","author":"Kang","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3934\/genet.2018.3.177","article-title":"Panic disorders: The role of genetics and epigenetics","volume":"5","author":"Kim","year":"2018","journal-title":"AIMS Genet."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jad.2020.01.040","article-title":"Suicide epigenetics, a review of recent progress","volume":"265","author":"Cheung","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Park, H.-S., Kim, J., Ahn, S.H., and Ryu, H.-Y. (2021). Epigenetic Targeting of Histone Deacetylases in Diagnostics and Treatment of Depression. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105398"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/clpt.2011.282","article-title":"The epigenetic code in depression: Implications for treatment","volume":"91","author":"Schroeder","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1755-5949.2010.00203.x","article-title":"Histone deacetylases and mood disorders: Epigenetic programming in gene-environment interactions","volume":"17","author":"Ibrahim","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11920-007-0041-7","article-title":"Dopamine hypothesis of schizophrenia: Making sense of it all","volume":"9","author":"Toda","year":"2007","journal-title":"Curr. Psychiatry Rep."},{"key":"ref_169","unstructured":"Pletnikov, M., and Waddington, J. (2015). Modeling the Psychopathological Dimensions of Schizophrenia: From Molecules to Behavior, Academic Press."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbr.2014.07.016","article-title":"Recent advances in the neuropsychopharmacology of serotonergic hallucinogens","volume":"277","author":"Halberstadt","year":"2015","journal-title":"Behav. Brain Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation","volume":"27","author":"Preller","year":"2017","journal-title":"Curr. Biol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"107933","DOI":"10.1016\/j.neuropharm.2019.107933","article-title":"Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species","volume":"167","author":"Halberstadt","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.euroneuro.2016.01.005","article-title":"Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A\/2A agonist ergotamine on psilocybin-induced psychedelic experience","volume":"26","author":"Pokorny","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0166-4328(96)00081-2","article-title":"Human psychopharmacology of N,N-dimethyltryptamine","volume":"73","author":"Strassman","year":"1996","journal-title":"Behav. Brain Res."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","article-title":"5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man\u2014A PET study with [11C]raclopride","volume":"20","author":"Vollenweider","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"De Gregorio, D., Comai, S., Posa, L., and Gobbi, G. (2016). d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17111953"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00213-013-3006-z","article-title":"Characterization of the head-twitch response induced by hallucinogens in mice: Detection of the behavior based on the dynamics of head movement","volume":"227","author":"Halberstadt","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","article-title":"Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior","volume":"53","author":"Weisstaub","year":"2007","journal-title":"Neuron"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0165-6147(03)00167-6","article-title":"Ligand-selective receptor conformations revisited: The promise and the problem","volume":"24","author":"Kenakin","year":"2003","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_181","first-page":"315","article-title":"Discovering risperidone: The LSD model of psychopathology","volume":"2","author":"Colpaert","year":"2003","journal-title":"Nat. Rev."},{"key":"ref_182","first-page":"207","article-title":"Targeting metabotropic glutamate receptors to develop novel antipsychotics","volume":"30","author":"Chaki","year":"2010","journal-title":"Jpn. J. Psychopharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fpsyt.2019.00049","article-title":"Targeting mGlu Receptors for Optimization of Antipsychotic Activity and Disease-Modifying Effect in Schizophrenia","volume":"10","author":"Nicoletti","year":"2019","journal-title":"Front. Psychiatry"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0304-3940(87)90425-3","article-title":"Phencyclidine-induced head-twitch responses as 5-HT2 receptor-mediated behavior in rats","volume":"76","author":"Nabeshima","year":"1987","journal-title":"Neurosci. Lett."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/S0024-3205(98)00519-0","article-title":"NMDA receptor antagonists enhance 5-HT2 receptor-mediated behavior, head-twitch response, in mice","volume":"63","author":"Kim","year":"1998","journal-title":"Life Sci."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s007020050144","article-title":"The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice","volume":"106","author":"Carlsson","year":"1999","journal-title":"J. Neural Transm."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"14843","DOI":"10.1073\/pnas.0704848104","article-title":"Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine","volume":"104","author":"Kargieman","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1073\/pnas.0708862105","article-title":"Agonist-directed signaling of the serotonin 2A receptor depends on \u03b2-arrestin-2 interactions in vivo","volume":"105","author":"Schmid","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1734-1140(12)70746-6","article-title":"Protective effects of histamine H3-receptor ligands in schizophrenic behaviors in experimental models","volume":"64","author":"Mahmood","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"ref_191","first-page":"564","article-title":"Histamine H(3) receptors and its antagonism as a novel mechanism for antipsychotic effect: A current preclinical & clinical perspective","volume":"10","author":"Mahmood","year":"2016","journal-title":"Int. J. Health Sci."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1179069518800508","DOI":"10.1177\/1179069518800508","article-title":"Psychoplastogens: A Promising Class of Plasticity-Promoting Neurotherapeutics","volume":"12","author":"Olson","year":"2018","journal-title":"J. Exp. Neurosci."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/7854_2017_480","article-title":"Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons","volume":"36","author":"Marek","year":"2018","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1523\/JNEUROSCI.17-08-02785.1997","article-title":"5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex","volume":"17","author":"Vaidya","year":"1997","journal-title":"J. Neurosci."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"109836","DOI":"10.1016\/j.celrep.2021.109836","article-title":"Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice","volume":"37","author":"Zhu","year":"2021","journal-title":"Cell Rep."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics Promote Structural and Functional Neural Plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1021\/acsptsci.0c00099","article-title":"Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers","volume":"4","author":"Hutten","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","article-title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin","volume":"10","author":"Barrett","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/wps.20847","article-title":"The need for publicly funded research on therapeutic use of psychedelic drugs","volume":"20","author":"Hall","year":"2021","journal-title":"World Psychiatry"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/wps.20735","article-title":"Assessing the public health impacts of legalizing recreational cannabis use: The US experience","volume":"19","author":"Hall","year":"2020","journal-title":"World Psychiatry"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12954-021-00489-1","article-title":"Ethical and legal issues in psychedelic harm reduction and integration therapy","volume":"18","author":"Pilecki","year":"2021","journal-title":"Harm Reduct. J."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/5\/640\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:16:57Z","timestamp":1760138217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/5\/640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":201,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["ph15050640"],"URL":"https:\/\/doi.org\/10.3390\/ph15050640","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]}}}